Rubius Therapeutics (NASDAQ:RUBY) released its quarterly earnings results on Tuesday. The company reported ($0.50) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.04), Briefing.com reports. During the same period in the previous year, the company earned ($3.33) earnings per share.
NASDAQ:RUBY traded up $0.51 during mid-day trading on Friday, hitting $10.50. 55,275 shares of the company’s stock traded hands, compared to its average volume of 201,043. The company has a fifty day moving average of $13.91 and a 200 day moving average of $15.34. Rubius Therapeutics has a twelve month low of $9.96 and a twelve month high of $26.90. The company has a market capitalization of $834.03 million and a P/E ratio of -4.63. The company has a debt-to-equity ratio of 0.13, a quick ratio of 18.64 and a current ratio of 18.64.
In other Rubius Therapeutics news, Director Robert Langer sold 7,500 shares of the business’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $14.94, for a total transaction of $112,050.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Christopher L. Carpenter sold 47,757 shares of the business’s stock in a transaction dated Wednesday, June 19th. The shares were sold at an average price of $14.02, for a total value of $669,553.14. The disclosure for this sale can be found here. Corporate insiders own 58.40% of the company’s stock.
Several research firms have recently commented on RUBY. Zacks Investment Research raised Rubius Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 24th. Guggenheim began coverage on Rubius Therapeutics in a research report on Thursday, May 30th. They issued a “buy” rating and a $25.00 price target for the company. ValuEngine raised Rubius Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, HC Wainwright assumed coverage on Rubius Therapeutics in a research report on Wednesday, June 26th. They set a “buy” rating and a $40.00 target price on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $28.75.
Rubius Therapeutics Company Profile
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.
Featured Article: Catch-Up Contributions
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.